Efficacy and tolerability of eperisone in patients with spastic palsy

A cross-over, placebo-controlled dose-ranging trial

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background and Objectives: Central muscle relaxants are a clinical option in patients with spastic palsy. Eperisone is a central muscle relaxant used in several conditions, but its therapeutic potential in spastic palsy needs to be verified. This dose-ranging trial compares two doses of eperisone in patients with spastic palsy associated to cerebral or spinal diseases. Patients and Methods: In this randomized, placebo-controlled, double-blind, three-way cross-over study, patients (18-75 years) with spastic palsy received eperisone 150 mg/day, eperisone 300 mg/day, or placebo for 8 weeks. Treatment periods lasted for 14 days. Objective clinical parameters (intensity of spasticity and physiological reflexes) and functional parameters (walking capability, capability to climb stairs, rigidity) were measured. Tolerability was also evaluated. Results: Eighteen patients were enrolled. The reduction in the intensity of spasticity versus the beginning of each treatment cycle was significant with eperisone 300 mg/day (p =0.004). Similar findings were observed in the evaluation of patellar reflex (p =0.01), while the other reflexes were not significantly different. Walking capability was significantly improved with eperisone 300 mg/day (p

Original languageEnglish
Pages (from-to)365-370
Number of pages6
JournalEuropean Review for Medical and Pharmacological Sciences
Volume13
Issue number5
Publication statusPublished - Sep 2009

Fingerprint

Muscle Spasticity
Paralysis
Placebos
Central Muscle Relaxants
Reflex
Walking
Spinal Diseases
Cross-Over Studies
eperisone
Therapeutics

Keywords

  • Central muscle relaxants
  • Eperisone
  • Spastic palsy

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology (medical)

Cite this

@article{5df93f30a54143c8b9e495c6634c4992,
title = "Efficacy and tolerability of eperisone in patients with spastic palsy: A cross-over, placebo-controlled dose-ranging trial",
abstract = "Background and Objectives: Central muscle relaxants are a clinical option in patients with spastic palsy. Eperisone is a central muscle relaxant used in several conditions, but its therapeutic potential in spastic palsy needs to be verified. This dose-ranging trial compares two doses of eperisone in patients with spastic palsy associated to cerebral or spinal diseases. Patients and Methods: In this randomized, placebo-controlled, double-blind, three-way cross-over study, patients (18-75 years) with spastic palsy received eperisone 150 mg/day, eperisone 300 mg/day, or placebo for 8 weeks. Treatment periods lasted for 14 days. Objective clinical parameters (intensity of spasticity and physiological reflexes) and functional parameters (walking capability, capability to climb stairs, rigidity) were measured. Tolerability was also evaluated. Results: Eighteen patients were enrolled. The reduction in the intensity of spasticity versus the beginning of each treatment cycle was significant with eperisone 300 mg/day (p =0.004). Similar findings were observed in the evaluation of patellar reflex (p =0.01), while the other reflexes were not significantly different. Walking capability was significantly improved with eperisone 300 mg/day (p",
keywords = "Central muscle relaxants, Eperisone, Spastic palsy",
author = "Nereo Bresolin and C. Zucca and A. Pecori",
year = "2009",
month = "9",
language = "English",
volume = "13",
pages = "365--370",
journal = "European Review for Medical and Pharmacological Sciences",
issn = "1128-3602",
publisher = "Verduci Editore",
number = "5",

}

TY - JOUR

T1 - Efficacy and tolerability of eperisone in patients with spastic palsy

T2 - A cross-over, placebo-controlled dose-ranging trial

AU - Bresolin, Nereo

AU - Zucca, C.

AU - Pecori, A.

PY - 2009/9

Y1 - 2009/9

N2 - Background and Objectives: Central muscle relaxants are a clinical option in patients with spastic palsy. Eperisone is a central muscle relaxant used in several conditions, but its therapeutic potential in spastic palsy needs to be verified. This dose-ranging trial compares two doses of eperisone in patients with spastic palsy associated to cerebral or spinal diseases. Patients and Methods: In this randomized, placebo-controlled, double-blind, three-way cross-over study, patients (18-75 years) with spastic palsy received eperisone 150 mg/day, eperisone 300 mg/day, or placebo for 8 weeks. Treatment periods lasted for 14 days. Objective clinical parameters (intensity of spasticity and physiological reflexes) and functional parameters (walking capability, capability to climb stairs, rigidity) were measured. Tolerability was also evaluated. Results: Eighteen patients were enrolled. The reduction in the intensity of spasticity versus the beginning of each treatment cycle was significant with eperisone 300 mg/day (p =0.004). Similar findings were observed in the evaluation of patellar reflex (p =0.01), while the other reflexes were not significantly different. Walking capability was significantly improved with eperisone 300 mg/day (p

AB - Background and Objectives: Central muscle relaxants are a clinical option in patients with spastic palsy. Eperisone is a central muscle relaxant used in several conditions, but its therapeutic potential in spastic palsy needs to be verified. This dose-ranging trial compares two doses of eperisone in patients with spastic palsy associated to cerebral or spinal diseases. Patients and Methods: In this randomized, placebo-controlled, double-blind, three-way cross-over study, patients (18-75 years) with spastic palsy received eperisone 150 mg/day, eperisone 300 mg/day, or placebo for 8 weeks. Treatment periods lasted for 14 days. Objective clinical parameters (intensity of spasticity and physiological reflexes) and functional parameters (walking capability, capability to climb stairs, rigidity) were measured. Tolerability was also evaluated. Results: Eighteen patients were enrolled. The reduction in the intensity of spasticity versus the beginning of each treatment cycle was significant with eperisone 300 mg/day (p =0.004). Similar findings were observed in the evaluation of patellar reflex (p =0.01), while the other reflexes were not significantly different. Walking capability was significantly improved with eperisone 300 mg/day (p

KW - Central muscle relaxants

KW - Eperisone

KW - Spastic palsy

UR - http://www.scopus.com/inward/record.url?scp=70450169261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70450169261&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 365

EP - 370

JO - European Review for Medical and Pharmacological Sciences

JF - European Review for Medical and Pharmacological Sciences

SN - 1128-3602

IS - 5

ER -